Here's why the Mayne Pharma (ASX:MYX) share price is shooting 28% higher

The Mayne Pharma Group Ltd (ASX:MYX) share price is shooting higher on Friday after gaining FDA approval for a new contraceptive pill…

| More on:
A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mayne Pharma Group Ltd (ASX: MYX) share price is shooting higher on Friday morning.

At the time of writing, the pharmaceutical company's shares are up a massive 28% to 59 cents.

This latest gain means the Mayne Pharma share price is now up 69% since the start of the year.

Why is the Mayne Pharma share price charging higher?

Investors have been buying the company's shares this morning following the release of a very positive announcement.

According to the release, the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) from Mayne Pharma and Mithra Pharmaceuticals for the novel combined oral contraceptive Nextstellis.

Following this approval, Mayne Pharma anticipates the commercial launch of Nextstellis by the end of June 2021.

What is Nextstellis?

Nextstellis was developed by Mithra and is the first and only contraceptive pill containing estetrol. This is a native estrogen which is now produced from a plant source. Estetrol is also the first new estrogen introduced in the US in more than 50 years.

The release explains that almost 10 million American women use short-acting combination (estrogen and progestin) contraceptives. This led to the US market for combined hormonal contraceptives generating US$3.6 billion in sales for the 12-month period ending January 2021 according to IQVIA.

Mayne Pharma has a 20-year exclusive license and supply agreement in the US and Australia for Nextstellis. The product is still under active review at the Australian Therapeutics Goods Administration.

Positively, the University of California's Professor and Director of Family Planning, Mitchell Creinin, spoke very positively about the product.

He said: "Nextstellis is a new innovative contraceptive that has been shown in clinical trials to be not only safe and effective but also well tolerated with a desirable bleeding profile and minimal impact on triglycerides, cholesterol and glucose, as well as weight and endocrine markers."

Management commentary

Given that the company considers this an important milestone, it isn't surprising to see the Mayne Pharma share price shooting higher.

The company's CEO, Scott Richards, commented "The approval of Nextstellis represents an important milestone, providing women with a new choice for their reproductive health. We are delighted to be introducing a new estrogen and bringing to market this novel, safe and effective option for women to consider with their healthcare providers."

"As a result of receiving FDA approval for Nextstellis, Mayne Pharma will pay Mithra US$11m in cash and issue 85.8m ordinary Mayne Pharma shares. Mithra is also entitled to a Mayne Pharma Board position. The new appointment will be subject to shareholder approval at the next Annual General Meeting in November 2021."

Based on the current Mayne Pharma share price, those shares are worth approximately $50.6 million.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Hands reaching high for a trophy with a sunset in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a cracking end to the trading week for ASX investors.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Gainers

Why ARB, Cleanaway, Hub24, and RPMGlobal shares are storming higher today

These shares are ending the week with a bang. But why?

Read more »

Five people in an office high five each other.
Technology Shares

5 best performing ASX 200 tech shares of FY25

Some of the technology sector's biggest names led the charge in share price growth last financial year.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX shares that rose 100%+ in FY25

Let's see why these shares delivered huge returns for their shareholders in the last financial year.

Read more »

Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a wild ride this Thursday.

Read more »

Excited couple celebrating success while looking at smartphone.
Share Gainers

Why Domino's, NRW, Pro Medicus, and WIA Gold shares are charging higher today

These shares are avoiding the market weakness and are pushing higher today. But why?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »

Happy man working on his laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX roared higher this hump day.

Read more »